These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38604294)

  • 1. PCSK9 inhibition and broad health outcomes: A Mendelian randomization phenome‑wide association study.
    Zhang K; Bian Q
    Pharmacol Res; 2024 May; 203():107177. PubMed ID: 38604294
    [No Abstract]   [Full Text] [Related]  

  • 2. Causal relationship between PCSK9 inhibitor and primary glomerular disease: a drug target Mendelian randomization study.
    Duan H; Shi Y; Zhang Q; Shi X; Zhang Y; Liu J; Zhang Y
    Front Endocrinol (Lausanne); 2024; 15():1335489. PubMed ID: 38510702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of PCSK9 inhibitors should be avoided during pregnancy: results from a Mendelian randomization study.
    Efird JT
    Eur J Prev Cardiol; 2024 Jun; 31(8):954. PubMed ID: 38225181
    [No Abstract]   [Full Text] [Related]  

  • 4. PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis.
    Chen DQ; Xu WB; Xiao KY; Que ZQ; Feng JY; Sun NK; Cai DX; Rui G
    BMC Musculoskelet Disord; 2024 Jul; 25(1):548. PubMed ID: 39010016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomic Signatures of Genetically Predicted and Pharmacologically Observed PCSK9 Inhibition.
    Kraaijenhof JM; Cronjé HT; Hovingh GK; Nurmohamed NS; Gill D; Zagkos L
    J Am Heart Assoc; 2024 Jun; 13(12):e033190. PubMed ID: 38874077
    [No Abstract]   [Full Text] [Related]  

  • 6. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study.
    He JY; Zhang X; Wang K; Lv WQ
    J Nutr; 2022 May; 152(5):1283-1290. PubMed ID: 35349717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study.
    Xie W; Li J; Du H; Xia J
    Arthritis Res Ther; 2023 Aug; 25(1):148. PubMed ID: 37580807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Causal relationship between PCSK9 inhibitor and common neurodegenerative diseases: A drug target Mendelian randomization study.
    Huang Q; Zhang Q; Cao B
    Brain Behav; 2024 Jun; 14(6):e3543. PubMed ID: 38837845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between genetically proxied PCSK9 inhibition and systemic lupus erythematosus risk: A mendelian randomization study.
    Ji X; Guo HY; Han M; Peng H; Yuan H
    Int J Rheum Dis; 2024 Apr; 27(4):e15106. PubMed ID: 38568054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function.
    Rosoff DB; Bell AS; Jung J; Wagner J; Mavromatis LA; Lohoff FW
    J Am Coll Cardiol; 2022 Aug; 80(7):653-662. PubMed ID: 35953131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Causal association between lipid-lowering drugs and female reproductive endocrine diseases: a drug-targeted Mendelian randomization study.
    Zhao J; Wang R; Song L; Han H; Wang P; Zhao Y; Zhang Y; Zhang H
    Front Endocrinol (Lausanne); 2023; 14():1295412. PubMed ID: 38027179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Causal Relationship between PCSK9 Inhibitors and Malignant Tumors: A Mendelian Randomization Study Based on Drug Targeting.
    Wang W; Li W; Zhang D; Mi Y; Zhang J; He G
    Genes (Basel); 2024 Jan; 15(1):. PubMed ID: 38275613
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluating the Cardiovascular Impact of Genetically Proxied PCSK9 and HMGCR Inhibition in East Asian and European Populations: A Drug-Target Mendelian Randomization Study.
    Rosoff DB; Bell AS; Mavromatis LA; Hamandi A; Park L; Jung J; Wagner J; Pacher P; Ray D; Davey Smith G; Lohoff FW
    Circ Genom Precis Med; 2024 Feb; 17(1):e004224. PubMed ID: 38258565
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparing the Relationships of Genetically Proxied PCSK9 Inhibition With Mood Disorders, Cognition, and Dementia Between Men and Women: A Drug-Target Mendelian Randomization Study.
    Bell AS; Rosoff DB; Mavromatis LA; Jung J; Wagner J; Lohoff FW
    J Am Heart Assoc; 2022 Nov; 11(21):e026122. PubMed ID: 36285785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.
    Schmidt AF; Holmes MV; Preiss D; Swerdlow DI; Denaxas S; Fatemifar G; Faraway R; Finan C; Valentine D; Fairhurst-Hunter Z; Hartwig FP; Horta BL; Hypponen E; Power C; Moldovan M; van Iperen E; Hovingh K; Demuth I; Norman K; Steinhagen-Thiessen E; Demuth J; Bertram L; Lill CM; Coassin S; Willeit J; Kiechl S; Willeit K; Mason D; Wright J; Morris R; Wanamethee G; Whincup P; Ben-Shlomo Y; McLachlan S; Price JF; Kivimaki M; Welch C; Sanchez-Galvez A; Marques-Vidal P; Nicolaides A; Panayiotou AG; Onland-Moret NC; van der Schouw YT; Matullo G; Fiorito G; Guarrera S; Sacerdote C; Wareham NJ; Langenberg C; Scott RA; Luan J; Bobak M; Malyutina S; Pająk A; Kubinova R; Tamosiunas A; Pikhart H; Grarup N; Pedersen O; Hansen T; Linneberg A; Jess T; Cooper J; Humphries SE; Brilliant M; Kitchner T; Hakonarson H; Carrell DS; McCarty CA; Lester KH; Larson EB; Crosslin DR; de Andrade M; Roden DM; Denny JC; Carty C; Hancock S; Attia J; Holliday E; Scott R; Schofield P; O'Donnell M; Yusuf S; Chong M; Pare G; van der Harst P; Said MA; Eppinga RN; Verweij N; Snieder H; ; Christen T; Mook-Kanamori DO; ; Gustafsson S; Lind L; Ingelsson E; Pazoki R; Franco O; Hofman A; Uitterlinden A; Dehghan A; Teumer A; Baumeister S; Dörr M; Lerch MM; Völker U; Völzke H; Ward J; Pell JP; Meade T; Christophersen IE; Maitland-van der Zee AH; Baranova EV; Young R; Ford I; Campbell A; Padmanabhan S; Bots ML; Grobbee DE; Froguel P; Thuillier D; Roussel R; Bonnefond A; Cariou B; Smart M; Bao Y; Kumari M; Mahajan A; Hopewell JC; Seshadri S; ; Dale C; Costa RPE; Ridker PM; Chasman DI; Reiner AP; Ritchie MD; Lange LA; Cornish AJ; Dobbins SE; Hemminki K; Kinnersley B; Sanson M; Labreche K; Simon M; Bondy M; Law P; Speedy H; Allan J; Li N; Went M; Weinhold N; Morgan G; Sonneveld P; Nilsson B; Goldschmidt H; Sud A; Engert A; Hansson M; Hemingway H; Asselbergs FW; Patel RS; Keating BJ; Sattar N; Houlston R; Casas JP; Hingorani AD
    BMC Cardiovasc Disord; 2019 Oct; 19(1):240. PubMed ID: 31664920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels and Its Impact on Atherosclerotic Vascular Disease Phenotypes.
    Pott J; Schlegel V; Teren A; Horn K; Kirsten H; Bluecher C; Kratzsch J; Loeffler M; Thiery J; Burkhardt R; Scholz M
    Circ Genom Precis Med; 2018 May; 11(5):e001992. PubMed ID: 29748315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein(a) lowering and cardiovascular risk reduction by PCSK9 inhibitors.
    Safarova MS; Kullo IJ
    Atherosclerosis; 2022 Nov; 361():30-31. PubMed ID: 36344291
    [No Abstract]   [Full Text] [Related]  

  • 18. Investigating the potential impact of PCSK9-inhibitors on mood disorders using eQTL-based Mendelian randomization.
    Aman A; Slob EAW; Ward J; Cullen B; Graham N; Lyall DM; Sattar N; Strawbridge RJ
    PLoS One; 2022; 17(12):e0279381. PubMed ID: 36580462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring PCSK9 Genetic Impact on Lipoprotein(a) via Dual Approaches: Association and Mendelian Randomization.
    Chang YC; Hsu LA; Ko YL
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common and Rare
    Hsu LA; Teng MS; Wu S; Chou HH; Ko YL
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.